Last reviewed · How we verify
Standard treatment strategy
This drug works by inhibiting the reabsorption of sodium and water in the kidneys.
This drug works by inhibiting the reabsorption of sodium and water in the kidneys. Used for Type 2 diabetes, Heart failure.
At a glance
| Generic name | Standard treatment strategy |
|---|---|
| Sponsor | Fundación para la Investigación del Hospital Clínico de Valencia |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
By blocking the sodium-glucose cotransporter 2 (SGLT2), the drug reduces glucose reabsorption in the kidneys, leading to decreased glucose levels in the blood. This mechanism also results in the excretion of excess sodium and water, contributing to its diuretic effects.
Approved indications
- Type 2 diabetes
- Heart failure
Common side effects
- Increased risk of diabetic ketoacidosis
- Increased risk of genital yeast infections
- Increased risk of hypotension
- Increased risk of acute kidney injury
- Increased risk of urinary tract infections
Key clinical trials
- Study of a Support Program for Quality of Life in Chinese Cancer Patients and Survivors (NA)
- Impact of a Mindfulness Intervention on Infertile Women Undergoing Assisted Reproductive Technique Treatments (NA)
- Nutritional Ketosis Marfan (NA)
- Evidence-Based Nursing Plus Progressive Exercise for Cancer-Related Fatigue in Advanced Lung Cancer (NA)
- Use of Crohn's Disease Exclusion Diet on Top of Standard Therapy Versus Standard Therapy Alone in Unstable Pediatric Crohn's Disease Patients. (PHASE3)
- Program for Fully Understanding Eating and Lifestyle Change (FUEL) (NA)
- Dyad Plus Effectiveness/Feasibility (NA)
- Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: